IMR Press / EJGO / Volume 18 / Issue 1 / pii/1997109

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma

Show Less
1 Sierra Medical Center, Department of Medical Oncology, El Paso, Texas, USA
2 The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Eur. J. Gynaecol. Oncol. 1997, 18(1), 39–41;
Published: 10 February 1997
Abstract

Primary peritoneal papillary serous adenocarcinoma is histologically identical to ovarian papillary serous adenocarcinoma. This diagnosis is made if the ovaries are of normal size with either no tumor or only minimal surface involvement. We describe a patient with a primary peritoneal papillary serous adenocarcinoma which was resistant to initial therapy with pacli­taxel, but subsequently achieved a partial response with carboplatin-based chemotherapy. Accordingly, carboplatin therapy should be considered in paclitaxel resistant primary peritoneal papillary serous carcinoma.

Keywords
Carboplatin
Peritoneal papillary serous carcinoma
Paclitaxel
Share
Back to top